Physician profile
Michael Lampe
NPI 1245897834
$6,832.90
in general payments reported to CMS, 2019-2025
11 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 79% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,181 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,789 · Travel and Lodging: $2,546 · Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,789.07 |
| Travel and Lodging | $2,546.44 |
| Food and Beverage | $1,497.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,195.42 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $1,078.09 | 2024 | Gore Bio-A Tissue Reinforcement, Gore Enform Preperitoneal Biomaterial, Gore Synecor Biomaterial |
| Lilly USA, LLC | $129.99 | 2024-2025 | Omvoh |
| Mesh Suture INC | $114.39 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.43 | 2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $63.37 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $48.88 | 2025 | Rezdiffra |
| Ethicon US, LLC | $43.10 | 2025 | Enseal, Harmonic, Endopath Xcel |
| Regeneron Healthcare Solutions, INC. | $27.73 | 2024 | Dupixent |
| Abbvie INC. | $19.56 | 2024 | |
| Aimmune Therapeutics, INC. | $18.94 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lampe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.